Gilead Sciences, Inc. (GILD) Wednesday said it presented encouraging long-term data from ALLIANCE study.
ALLIANCE is an ongoing Phase 3 study to evaluate Biktarvy versus dolutegravir plus emtricitabine/tenofovir disoproxil fumarate F/TDF, DTG+F/TDF, in adults with HIV-1/HBV co-infection initiating treatment.
New data from the study showed that Biktarvy maintained 95.4% of HIV-1 and 86.6% of HBV virologic suppression in participants following a switch to Biktarvy after 96 weeks of treatment with DTG+ F/TDF.
These data were presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2025).
Additionally, the company said its Phase 2 study of lenacapavir with teropavimab and zinlirvimab (LTZ) met its primary goal of proportion of participants with HIV-1 RNA = 50 copies/mL at Week 26.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.